delta-9-tetrahydrocannabinol
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04855526 | Dec 2025 → Dec 2026 expected | cannabis dependence | Hartford Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06471647 | Jul 2024 → Mar 2025 | — | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT05935891 | Feb 2023 → Apr 2024 | musculoskeletal system disorder | University of Minnesota | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT05067387 | Aug 2026 → Jun 2027 expected | drug-induced mental disorder, substance abuse | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 1 | NCT06222268 | Mar 2026 → Sep 2031 expected | post-traumatic stress disorder | Wayne State University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02492074 | Dec 2024 → Apr 2025 | substance-induced psychosis | Central Institute of Mental Health, Mannheim | Withdrawn | No outcome recorded |
| Phase 1 | NCT05037487 | Sep 2022 → Jan 2025 | drug-induced mental disorder, substance abuse | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT04741477 | Jul 2021 → Sep 2022 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT03832816 | Dec 2019 → Dec 2021 | — | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT02487381 | Apr → Jul 2015 | substance-induced psychosis | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| Phase 1 | NCT00628706 | Apr → Sep 2008 | — | UMC Utrecht | Completed | No outcome recorded |
| Phase 1 | NCT01037608 | May 2007 → Aug 2011 | cannabis dependence, substance abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 1 | NCT00225407 | Jul → Dec 2005 | cardiac rhythm disease, hypotensive disorder | UMC Utrecht | Unknown | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT07839455 | Nov 2025 → Oct 2026 expected | psoriasis | Federal University of Latin American Integration | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03245658 | Oct 2017 → May 2018 | hypoproteinemia, hypercatabolic, malignant pancreatic neoplasm | Jens Rikardt Andersen | Withdrawn | No outcome recorded |
| Phase 2 | NCT01790555 | Jul → Oct 2013 | — | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01502046 | Sep 2011 → Jun 2012 | Huntington disease | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | Met primary |
| Phase 2 | NCT00377468 | Sep 2006 → Dec 2008 | complex regional pain syndrome | Ludwig-Maximilians - University of Munich | Unknown | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT01606137 | Feb 2002 → Dec 2004 | multiple sclerosis | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01610713 | May 2001 → Jul 2002 | multiple sclerosis | Jazz Pharmaceuticals | Completed | Missed primary |
| Phase not applicable5 trials · 1 met primary | ||||||
| — | NCT07471347 | Mar → Dec 2026 expected | psychiatric disorder | King's College London | Not yet recruiting | No outcome recorded |
| — | NCT04851392 | Mar 2019 → Jun 2021 | cannabis dependence | University College, London | Completed | Met primary |
| — | NCT05170217 | Nov 2017 → Jun 2019 | — | King's College London | Completed | No outcome recorded |
| — | NCT02061020 | Jan 2014 → Jul 2015 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00397605 | Nov 2006 → Dec 2013 | bipolar disorder | University of British Columbia | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy13 trials | ||||||
| Phase 0 | NCT05906511 Comparator | Oct 2023 → Apr 2026 overdue | substance abuse | Yale University | Recruiting | No outcome recorded |
| Phase 0 | NCT03215940 Comparator | Feb 2018 → Dec 2024 | chronic pain syndrome | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT03106363 Comparator | Jul 2017 → Jan 2020 | — | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 0 | NCT01853020 Comparator | Dec 2012 → Apr 2015 | psychotic disorder | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT00982982 Comparator | Feb 2009 → Feb 2013 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT00708994 Comparator | Feb 2008 → Dec 2012 | psychotic disorder | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT00678730 Comparator | Aug 2007 → Sep 2014 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02407808 Comparator | Feb 2015 → Aug 2018 overdue | cannabis dependence, psychotic disorder | Yale University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01740960 Comparator | Aug → Dec 2012 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05543681 Comparator | Oct 2022 → Nov 2026 expected | Alzheimer disease | IGC Pharma, LLC | Active not recruiting | No outcome recorded |
| — | NCT02560545 Comparator | Sep 2015 → Sep 2019 | neuropathy, painful | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT02249299 Comparator | Aug 2014 → Jun 2015 | attention deficit-hyperactivity disorder | King's College London | Completed | No outcome recorded |
| — | NCT01592409 Comparator | Jul 2012 → Aug 2016 | — | Centre for Addiction and Mental Health | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 45 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | delta-9-tetrahydrocannabinol | “acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic...” NCT04855526 ↗37“Participants assigned to this arm will receive an oral full-spectrum cannabis extract containing cannabidiol (CBD), cannabigerol (CBG), and delta-9-tetrahydrocannabinol (THC)...” NCT07839455 ↗ “This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R)...” NCT02407808 ↗ “Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in...” NCT01606137 ↗ “The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.” NCT01853020 ↗ “Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).” NCT02249299 ↗ “Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users” NCT02061020 ↗ “The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony.” NCT00708994 ↗ “The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin.” NCT05543681 ↗ “Delta(9)-Tetrahydrocannabinol (THC) is the main source of the pharmacological effects caused by the consumption of cannabis” PMID 12648025 ↗ 2003 “An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis” NCT01610713 ↗ |
| Known as | Delta-9-THC | “Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol.” NCT00982982 ↗ |
| Known as | Namisol | “The purpose of this study is to investigate the analgesic and pain modulating effects of perioperative Namisol, a tablet containing THC, in patients that will undergo major...” NCT01790555 ↗ |
| Known as | THC | “Participants assigned to this arm will receive an oral full-spectrum cannabis extract containing cannabidiol (CBD), cannabigerol (CBG), and delta-9-tetrahydrocannabinol (THC)...” NCT07839455 ↗30“Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in...” NCT01606137 ↗ “Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).” NCT02249299 ↗ “An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.” NCT03215940 ↗ “The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin.” NCT05543681 ↗ “Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.” NCT01610713 ↗ “The two main phytocannabinoids-delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)-have been extensively studied” PMID 33304282 ↗ Nov 2020 “THC condition: Cannabis with delta-9-tetrahydrocannabinol (THC) and no cannabidiol (CBD). 0.107mg/kg of THC.” NCT04851392 ↗ “the administration of Δ9-Tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis” PMID 28642081 ↗ Jun 2017 “Women were randomized 1:1 to cannabidiol (CBD) vs. delta-9-tetrahydrocannabinol (THC) balms.” PMID 41467893 ↗ Dec 2025 “These two compounds are: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).” NCT00397605 ↗ |
| Known as | Δ9-tetrahydrocannabinol | “after inhaling cannabis with 0.107 mg/kg Δ⁹-tetrahydrocannabinol ("THC") (8 mg THC for a 75-kg person) or with THC plus 0.320 mg/kg cannabidiol ("THC+CBD") (24 mg CBD for a...” PMID 36642667 ↗ Oct 20224“the acute effects of Δ9-tetrahydrocannabinol (THC) on attentional bias to cannabis cues, the differential response in adults and adolescents, and the moderating effect of...” PMID 38416223 ↗ Feb 2024 “the administration of Δ9-Tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis” PMID 28642081 ↗ Jun 2017 “the effects of δ-9-tetrahydrocannabinol (THC), an emerging treatment option” PMID 38597988 ↗ Apr 2024 “Δ9-Tetrahydrocannabinol (THC) is the psychoactive component in cannabis” PMID 36730769 ↗ Feb 2023 |
| Known as | Δ9-THC | “The study examines the effects of delta-9-tetrahydrocannabinol (Δ9-THC), the principal active ingredient of cannabis, on neural synchrony.” NCT00708994 ↗ |
| Known as | ∆9-THC | “The purpose of this study is to characterize the dose-related effects of delta-9-tetrahydrocannabinol (∆9-THC) in healthy individuals on cerebellum-dependent motor functions.” NCT01853020 ↗1“delta-9-tetrahydrocannabinol (∆-9-THC or THC)” NCT00982982 ↗ |
| Action | Activate | “Cannabinoids exert many effects through activation of G-protein-coupled cannabinoid receptors in the brain and peripheral tissues.” PMID 12648025 ↗ 2003 |
| Modality | Other / unclassified | “phytocannabinoids delta-9-tetrahydrocannabinol, cannabidiol” NCT02492074 ↗ |
| Route | Inhaled | “inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer” NCT00628706 ↗ |